About the cheap stock I agree. But I am getting more and more enthousiastic about the strategic character of this deal. The french are ready for the transgenic platform and wether they develop transgenic products in cooperation with GTCB or under license of GTCB, the faster the platform gets widespread adoption, the earlier GTCB's IP will become the cash cow, we all want it to be.
I second the thanks...funny how anti-GMO Europe was about their food and how accepting they are of GMO medicine. I guess with socialized health care, cost becomes such a driving force.
Market Data 
Markets 
AI
